56973-41-2

56973-41-2 structure

Name: Withanolide B
Chemical Name: Lycium substance B
CAS Number: 56973-41-2
Molecular Formula: C₂₈H₃₈O₅
Molecular Weight: 454.59800
Catalog: analytical chemistry Analytical reagent Ion chromatography reagent
Create Date: 2016-08-03 18:46:09
Modify Date: 2025-08-27 09:02:29
Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via ERK1/2 and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects[1][2][3].

Name	Lycium substance B
Synonyms	UNII-9YU877VU8K Withanolide B

Description	Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via ERK1/2 and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects[1][2][3].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Stem Cell/Wnt >> Wnt Research Areas >> Inflammation/Immunology Research Areas >> Metabolic Disease Signaling Pathways >> MAPK/ERK Pathway >> ERK Research Areas >> Neurological Disease Signaling Pathways >> Stem Cell/Wnt >> ERK
In Vitro	Withanolide B (1-100 nM; 3-5 days) significantly increases the expression of COL1A1 and RUNX2 genes and proteins in hBMSCs[1]. Withanolide B (1-100 nM; 11 or 3 days) increases the formation of extracellular matrix calcium deposits and increased the activity of alkaline phosphatase (ALP)[1]. Withanolide B (1-100 nM; 3-5 days) increases the protein expressions of p-ERK and active β-catenin of hBMSCs[1]. Withanolide B (10-100 μM; 48 h) reverses the Aβ42 aggregation-induced toxicy in SK-N-SH cells[2]. Cell Viability Assay[1] Cell Line: Human bone mesenchymal stem cells Concentration: 1, 10, 100 nM Incubation Time: 3, 5 days Result: Significantly increased the expression of COL1A1 and RUNX2.
In Vivo	Withanolide B (10 mg/kg; topical administration) promotes bone healing in a rat tibial defect model[1]. Animal Model: Male Sprague-Dawley rats (8 weeks, 200 g) with tibial defect[1] Dosage: 10 mg/kg Administration: Injected in situ at the bone defect site at different time points (0, 3, 5, 7, and 9 days) Result: Increased the trabecular number, trabecular thickness and the thickness of the cortical bone.
References	[1]. Kuang Z, et, al. Withanolide B promotes osteogenic differentiation of human bone marrow mesenchymal stem cells via ERK1/2 and Wnt/β-catenin signaling pathways. Int Immunopharmacol. 2020 Nov;88:106960. [2]. Dubey S, et, al. Improving the inhibition of β-amyloid aggregation by withanolide and withanoside derivatives. Int J Biol Macromol. 2021 Mar 15;173:56-65. [3]. Sivanandha G, et, al. Enhanced biosynthesis of withanolides by elicitation and precursor feeding in cell suspension culture of Withania somnifera (L.) Dunal in shake-flask culture and bioreactor. PLoS One. 2014 Aug 4;9(8):e104005.

Density	1.206
Molecular Formula	C₂₈H₃₈O₅
Molecular Weight	454.59800
Exact Mass	454.27200
PSA	76.13000
LogP	4.38050

Hazard Statements	H413
RIDADR	NONH for all modes of transport

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

56973-41-2	105708-64-3
140852-71-7	121923-96-4
113900-78-0	105650-11-1
100046-03-5	107745-54-0
929974-17-4	132246-31-2
1786525-42-5	1786639-50-6
1786899-70-4	1787308-28-4
1786843-00-2	1786752-15-5
1787187-75-0	1787071-90-2
1786505-75-6	1786727-11-4